<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; company</title>
	<atom:link href="http://www.tapanray.in/tag/company/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Leadership Challenge In Post Covid Paradigm</title>
		<link>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-leadership-challenge-in-post-covid-paradigm</link>
		<comments>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/#comments</comments>
		<pubDate>Mon, 03 Oct 2022 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitally]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field]]></category>
		<category><![CDATA[focussed]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[post covid]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[presence]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[share of voice]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10713</guid>
		<description><![CDATA[Bringing a long cherished relief to many, on September 15, 2022, the World Health Organization said, &#8216;we can see the Finish Line&#8217; for the COVID-19 pandemic but it&#8217;s not over yet’. As I see today, several things are changing pretty fast &#8230; <a href="http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Impact of The Cost of Pharma Marketing Failure On Patients</title>
		<link>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=impact-of-the-cost-of-pharma-marketing-failure-on-patients</link>
		<comments>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/#comments</comments>
		<pubDate>Mon, 12 Sep 2022 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[controllable]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[send]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[uncontrollable]]></category>
		<category><![CDATA[variables]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10707</guid>
		<description><![CDATA[‘About half of all products launched over the past 15 years have underperformed pre-launch consensus forecasts by more than 20%.’ It’s one of the findings of a recent study by L.E.K. Consulting, going back to 2004. This number is besides the cost of &#8230; <a href="http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/impact-of-the-cost-of-pharma-marketing-failure-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Visible, The Green Shoots of Digital Transformation in Pharma</title>
		<link>http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=visible-the-green-shoots-of-digital-transformation-in-pharma</link>
		<comments>http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/#comments</comments>
		<pubDate>Mon, 22 Jul 2019 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDO]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[green]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Internet of Things]]></category>
		<category><![CDATA[IoT]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[rationalization]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulated]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[shoots]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[temporary]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[warming-up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9636</guid>
		<description><![CDATA[Currently, one gets a mixed feeling about the progress of digital transformation in the pharma industry. This is despite various reports confirming that a number of major initiatives in this field have been taken, especially by Big Pharma, globally. Moreover, &#8230; <a href="http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/visible-the-green-shoots-of-digital-transformation-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Quality Imbroglio And ‘Culture of Bending Rules’ in India</title>
		<link>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-quality-imbroglio-and-culture-of-bending-rules-in-india</link>
		<comments>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/#comments</comments>
		<pubDate>Mon, 27 May 2019 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bending]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[culpable]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[Culture of Bending Rules]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[letter]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[multinational]]></category>
		<category><![CDATA[negative]]></category>
		<category><![CDATA[non-branded]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[quagmire]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[questionable]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[rules]]></category>
		<category><![CDATA[specific]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[US-FDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9539</guid>
		<description><![CDATA[“Bottle Of Lies Exposes The Dark Side Of The Generic-Drug Boom” &#8211; re-emphasized the book, released in May 2019.  This confirms, the raging debate on the questionable quality of many generic drugs manufactured in India and involving several top domestic pharma companies, &#8230; <a href="http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-quality-imbroglio-and-culture-of-bending-rules-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Pharma Communication In Sync With Doctors’ Expectations?</title>
		<link>http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-pharma-communication-in-sync-with-doctors-expectations</link>
		<comments>http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/#comments</comments>
		<pubDate>Mon, 13 May 2019 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[allocation]]></category>
		<category><![CDATA[bridging]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disconnect]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[gaps]]></category>
		<category><![CDATA[in-sync]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[monitoring]]></category>
		<category><![CDATA[non-personal]]></category>
		<category><![CDATA[outreach]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Resource]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[worldwide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9527</guid>
		<description><![CDATA[Not many pharma companies, especially in India, undertake any ongoing data-based analysis to gain insight on expectations and change in behavioral pattern of their customers, particularly doctors and patients. Many developments are taken as obvious, such as, when busy practitioners &#8230; <a href="http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Unbossing’ Pharma Culture For Millennials – A Sine Qua Non For Future Growth</title>
		<link>http://www.tapanray.in/unbossing-pharma-culture-for-millennials-a-sine-qua-non-for-future-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unbossing-pharma-culture-for-millennials-a-sine-qua-non-for-future-growth</link>
		<comments>http://www.tapanray.in/unbossing-pharma-culture-for-millennials-a-sine-qua-non-for-future-growth/#comments</comments>
		<pubDate>Mon, 31 Dec 2018 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[C-suite]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[Sine Qua Non]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traits]]></category>
		<category><![CDATA[unboss]]></category>
		<category><![CDATA[unbossing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9333</guid>
		<description><![CDATA[Wishing All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2019 ‘Unbossing’ an organizational culture is an interesting idea – more in the context of promoter driven Indian drug companies of all sizes and scale. The word – ‘unboss’ is &#8230; <a href="http://www.tapanray.in/unbossing-pharma-culture-for-millennials-a-sine-qua-non-for-future-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unbossing-pharma-culture-for-millennials-a-sine-qua-non-for-future-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Trees Die From The Top: Apt For Pharma Leadership Too?</title>
		<link>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=trees-die-from-the-top-apt-for-pharma-leadership-too</link>
		<comments>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/#comments</comments>
		<pubDate>Mon, 22 Oct 2018 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[appraisal]]></category>
		<category><![CDATA[apt]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[dies]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[measurement]]></category>
		<category><![CDATA[metric]]></category>
		<category><![CDATA[Narasimhan]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[Tree]]></category>
		<category><![CDATA[Vas]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9229</guid>
		<description><![CDATA[The Management Guru of all-time &#8211; Peter F. Drucker once said: &#8220;The spirit of an organization is created from the top… If an organization is great in spirit, it is because the spirit of its top people is great.” As &#8230; <a href="http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/trees-die-from-the-top-apt-for-pharma-leadership-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Design Thinking’: Translating Struggles into Positive Outcomes in Pharma</title>
		<link>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=design-thinking-translating-struggles-into-positive-outcomes-in-pharma</link>
		<comments>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/#comments</comments>
		<pubDate>Mon, 24 Sep 2018 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[design]]></category>
		<category><![CDATA[Design thinking]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[prototype]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[solving]]></category>
		<category><![CDATA[struggles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thinking]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9196</guid>
		<description><![CDATA[Problems of various nature will keep coming on business, as long as long as one remains in the business. It doesn’t spare anyone in the organization – from the very top to right up to the very bottom. All is &#8230; <a href="http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Sine Qua Non to Pharma Success in Digitized World</title>
		<link>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-sine-qua-non-to-pharma-success-in-digitized-world</link>
		<comments>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/#comments</comments>
		<pubDate>Mon, 16 Oct 2017 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalization]]></category>
		<category><![CDATA[Pharma. Success.Digitized. World]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sine Qua Non]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8472</guid>
		<description><![CDATA[A wind of change is now blowing at an accelerated speed &#8211; encompassing virtually anything, across the world, including India, with a varying degree, though. It leaves a profound impact on the day to day lives of many, including almost &#8230; <a href="http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-sine-qua-non-to-pharma-success-in-digitized-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Governance Maladies and Corporate Leadership</title>
		<link>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-governance-maladies-and-corporate-leadership</link>
		<comments>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/#comments</comments>
		<pubDate>Sun, 01 Oct 2017 23:37:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[doctrine]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[maladies]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[managers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[shareholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8444</guid>
		<description><![CDATA[On September 26, 2017, two media headlines related to the Indian pharma industry, possibly made many wonder &#8211; Are these some of the key reasons prompting the Government to enforce stringent and costly regulations in this sector? Above revelations came &#8230; <a href="http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
